Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | INMT | O95050 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14600514 | 0.79 | CA12 (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL7468780 | 0.77 | CA2 (0.57) | CA12CA1CA2CA9TDP1 | |
| Water SCHEMBL5851690 | 0.74 | LMNA (0.45) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL19296834 | 0.74 | CA12 (0.40) | CA12CA1CA2CA9HTR6 | |
| SCHEMBL13696855 | 0.74 | SMN1; SMN2 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| Water SCHEMBL5851692 | 0.74 | CA12 (0.40) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL28274645 | 0.72 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL31713547 | 0.70 | HTT (0.39) | ALDH1A1HSD17B10TDP1HTR6 | |
| SCHEMBL31713652 | 0.70 | ALDH1A1 (0.34) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL28063702 | 0.70 | ALDH1A1 (0.44) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023018473-A1 | COMBINED DETERMINATION OF THE CONCENTRATION AND ENANTIOMERIC COMPOSITION OF CHIRAL COMPOUNDS USING SINGLE CHIROPTICAL ASSAY | GEORGETOWN UNIVERSITY (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-2396296-B1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9096619-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9067871-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140031331-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8563617-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-10-22 | — | — | US | disclosed |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-2396296-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2010092180-A1 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031331-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, GFPT1, BCAT1 | CA12 3008/4885CA1 2239/4885CA2 590/4885 |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | AADAT, GFPT1, BCAT1 | CA12 3368/4885CA1 2571/4885CA2 807/4885 |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, GFPT1, BCAT1 | CA12 3008/4885CA1 2239/4885CA2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.